Molecular Pathology of Digestion Laboratory, A.I. Yevdokimov Moscow State University of Medicine and Dentistry, Delegatskaya Str., 20/1, 127473 Moscow, Russia.
Scientific Research Institute for Systems Biology and Medicine, Nauchniy Proezd, 18, 117246 Moscow, Russia.
Int J Mol Sci. 2023 Mar 28;24(7):6372. doi: 10.3390/ijms24076372.
Life expectancy and age-related diseases burden increased significantly over the past few decades. Age-related conditions are commonly discussed in a very limited paradigm of depleted cellular proliferation and maturation with exponential accumulation of senescent cells. However, most recent evidence showed that the majority of age-associated ailments, i.e., diabetes mellitus, cardiovascular diseases and neurodegeneration. These diseases are closely associated with tissue nonspecific inflammation triggered and controlled by mesenchymal stromal cell secretion. Mesenchymal stromal cells (MSCs) are known as the most common type of cells for therapeutic approaches in clinical practice. Side effects and complications of MSC-based treatments increased interest in the MSCs secretome as an alternative concept for validation tests in regenerative medicine. The most recent data also proposed it as an ideal tool for cell-free regenerative therapy and tissue engineering. However, senescent MSCs secretome was shown to hold the role of 'key-driver' in inflammaging. We aimed to review the immunomodulatory effects of the MSCs-secretome during cell senescence and provide eventual insight into the interpretation of its beneficial biological actions in inflammaging-associated diseases.
在过去的几十年里，预期寿命和与年龄相关的疾病负担显著增加。与年龄相关的疾病通常在细胞增殖和成熟能力下降以及衰老细胞指数积累的有限范式中进行讨论。然而，最近的证据表明，大多数与年龄相关的疾病，如糖尿病、心血管疾病和神经退行性疾病，都与由间充质基质细胞分泌触发和控制的组织非特异性炎症密切相关。间充质基质细胞（MSCs）被认为是临床治疗中最常见的细胞类型。基于 MSC 的治疗的副作用和并发症增加了对 MSC 分泌组作为再生医学验证试验替代概念的兴趣。最近的数据还提出它是无细胞再生治疗和组织工程的理想工具。然而，衰老的 MSC 分泌组被证明在炎症衰老中起着“关键驱动”的作用。我们旨在综述 MSC 分泌组在细胞衰老过程中的免疫调节作用，并为解释其在与炎症衰老相关的疾病中的有益生物学作用提供依据。
